The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models.
Systemic lupus erythematosus (SLE) is characterized in its early stages by the expansion of autoreactive T cells that trigger B-cell activation with subsequent multi-organ injury. Dendritic cells (DCs) in lupus were found to display an aberrant phenotype with higher expression of the maturation markers major histocompatibility complex (MHC) class II, CD80 and CD86, as well as higher production of proinflammatory cytokines including interleukin-12 (IL-12), resulting in an increased ability to activate T cells. A peptide (hCDR1) based on the complementarity determining region-1 of an anti-DNA antibody ameliorated SLE in both induced and spontaneous lupus models by downregulating T-cell functions. Our objectives were to determine whether DCs play a role in promoting the beneficial effects of hCDR1. We showed here that treatment with hCDR1 lowered the expression levels of MHC class II, CD80 and CD86 on DCs. The latter effect was associated with downregulation of messenger RNA expression and secretion of IL-12, a cytokine that upregulated T-cell proliferation and interferon-gamma (IFN-gamma) secretion. Moreover, DCs derived from hCDR1-treated mice downregulated proliferation and IFN-gamma secretion by T cells from untreated mice. Upregulation of transforming growth factor-beta (TGF-beta) secretion by T cells, following treatment with hCDR1, resulted in downregulation of IFN-gamma production and contributed to the phenotypic changes and magnitude of IL-12 secretion by DCs. The ameliorating effects of hCDR1 are therefore mediated at least partially by the upregulated secretion of TGF-beta by T cells that contribute to the induction of DCs with immature phenotype and suppressed functions. The resulting DCs further downregulate autoreactive T-cell functions.
Sela
Uri
U
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel.
Sharabi
Amir
A
Dayan
Molly
M
Hershkoviz
Rami
R
Mozes
Edna
E
D000818:Animals; D001324:Autoantigens / Q000494:pharmacology / Q000627:therapeutic use*; D018122:B7-1 Antigen / Q000187:drug effects / Q000276:immunology; D051940:B7-2 Antigen / Q000187:drug effects / Q000276:immunology; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D015536:Down-Regulation; D005260:Female; D000949:Histocompatibility Antigens Class II / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000819:agonists / Q000276:immunology / Q000378:metabolism; D018664:Interleukin-12 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000494:pharmacology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D009419:Nerve Tissue Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D015854:Up-Regulation
D001324:Autoantigens; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C063762:CDR1 protein, human; D000949:Histocompatibility Antigens Class II; D009419:Nerve Tissue Proteins; D010455:Peptides; D016212:Transforming Growth Factor beta; D018664:Interleukin-12; D007371:Interferon-gamma